Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Firazyr Generic Name & Formulations
Legal Class
Rx
General Description
Icatibant 10mg/mL; soln for SC inj; preservative-free.
Pharmacological Class
Bradykinin B2 receptor antagonist.
How Supplied
Single-use prefilled syringe (3mL)—1, 3
Manufacturer
Generic Availability
NO
Mechanism of Action
Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Firazyr Indications
Indications
For acute attacks of hereditary angioedema (HAE).
Firazyr Dosage and Administration
Adult
≥18yrs: 30mg SC in abdominal area; may give additional doses at intervals of at least 6hrs if response inadequate or symptoms recur. Max 3 doses/24hrs.
Children
<18yrs: not established.
Firazyr Contraindications
Not Applicable
Firazyr Boxed Warnings
Not Applicable
Firazyr Warnings/Precautions
Warnings/Precautions
Advise patients to seek medical attention after treating laryngeal attack given the potential for airway obstruction. Elderly. Pregnancy. Nursing mothers.
Firazyr Pharmacokinetics
Absorption
Absolute bioavailability: ~97%. Maximum plasma concentration: 974 ± 280 ng/mL (after ~0.75 hours).
Distribution
Volume of distribution (at steady state): 29.0 ± 8.7 L.
Elimination
Renal. Half-life: 1.4 ± 0.4 hours. Plasma clearance: 245 ± 58 mL/min.
Firazyr Interactions
Interactions
May attenuate the antihypertensive effect of ACE inhibitors.
Firazyr Adverse Reactions
Adverse Reactions
Inj site reactions, pyrexia, transaminase increase, dizziness, rash.
Firazyr Clinical Trials
See Literature
Firazyr Note
Not Applicable
Firazyr Patient Counseling
See Literature
Images
